共 50 条
- [41] THE ROLE OF IL-17, IL-23 SERUM LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS WITH INFLAMMATORY BOWEL DISEASESANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1551 - 1551Lukina, G.Kulakova, P.Alexandrova, E.Novikov, A.Savenkova, N.Klimets, A.Kartushina, I.Kovshik, A.Volnukhin, E.
- [42] New possibilities for overcoming the secondary inefficiency of anti-cytokine therapy in patients with inflammatory bowel diseasesTERAPEVTICHESKII ARKHIV, 2013, 85 (02) : 57 - 60Knyazev, O. V.Parfenov, A. I.Ruchkina, I. N.Konoplyannikov, A. G.Drozdov, V. N.Sagynbaeva, V. E.Ivkina, T. I.
- [43] LOW INCIDENCE OF BOTH NEW-ONSET AND FLARES OF UVEITIS IN SECUKINUMAB-TREATED PATIENTS WITH ANKYLOSING SPONDYLITIS: CLINICAL TRIAL AND POST-MARKETING SAFETY ANALYSISANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 999 - 999Deodhar, A.Miceli-Richard, C.Baraliakos, X.Marzo-Ortega, H.Gladman, D.Martin, R.Safi, J., Jr.Porter, B.Shete, A.
- [44] LOW INCIDENCE OF BOTH NEW-ONSET AND FLARES OF UVEITIS IN SECUKINUMAB-TREATED PATIENTS WITH ANKYLOSING SPONDYLITIS: CLINICAL TRIAL AND POST-MARKETING SAFETY ANALYSISRHEUMATOLOGY, 2019, 58 : 152 - 152Marzo-Ortega, HelenaDeodhar, AtulMiceli-Richard, CorinneBaraliakos, XenofonGladman, Dafna D.Martin, RuvieSafi, JorgePorter, BrianShete, Abhijit
- [45] Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety AnalysisARTHRITIS & RHEUMATOLOGY, 2018, 70Deodhar, Atul A.Miceli-Richard, CorinneBaraliakos, XenofonMarzo-Ortega, HelenaGladman, Dafna D.Martin, RuvieSafi, JorgePorter, BrianShete, Abhijit
- [46] A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapyMEDICAL SCIENCE MONITOR, 2014, 20 : 487 - 498Fonseca Chebli, Julio MariaGaburri, Pedro DuarteChebli, Liliana Andradeda Rocha Ribeiro, Tarsila CampanhaTavares Pinto, Andre LuizAmbrogini Junior, OrlandoMourao Cintra Damiao, Aderson Omar
- [47] Subclinical inflammatory changes in peripheral joints, tendons and entheses are common in patients initiating anti-TNFA therapy due to axial spondyloarthritis - An ultrasonographic studyANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 573 - 573Wiell, C.Sorensen, I. J.Hansen, M. S.Madsen, O. R.Majgaard, O.Thamsborg, G.Norregaard, J.Szkudlarek, M.Terslev, L.Ostergaard, M.
- [48] SERUM INDIAN HEDGEHOG (IHH) LEVELS ARE INCREASED IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS). ANTI-TNFA TREATMENT DECREASES SERUM IHH LEVELS IN PATIENTS WITH AS AND AFFECTS THE EXPRESSION OF FUNCTIONAL TARGET GENES IN A CELL LINE MODELANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 134 - 134Filippopoulou, A.Daoussis, D.Liossis, S. -N.Bouris, P.Klavdianou, K.Karamanos, N.Andonopoulos, A.
- [49] Predictive factors for chronic inflammatory bowel diseases in patients presenting with new onset diarrheaJOURNAL OF CROHNS & COLITIS, 2014, 8 : S130 - S131Singeap, A. -M.Trifan, A.Girleanu, I.Stoica, O. C.Stanciu, C.
- [50] PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFa OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRYGASTROENTEROLOGY, 2022, 162 (07) : S1007 - S1007Zacharopoulou, EiriniOrfanoudaki, EleniKitsou, VassilikiTzouvala, MariaTribonias, GeorgeMantzaris, Gerassimos J.Viazis, NikosChristidou, AngelikiGeorgiadi, TerezaKarmiris, KonstantinosTheodoropoulou, AngelikiTsafaridou, MariaMichopoulos, SpyridonZampeli, EvanthiaPapathanasiou, EvgeniaMichalopoulos, GeorgiosTigkas, StefanosKaratzas, PantelisLaoudi, EffrosyniLiatsos, ChristosKyriakos, NikolaosMylonas, IordanisTheocharis, Georgios J.Kafentzi, TheodoraKoutroubakis, Ioannis E.Bamias, Giorgos